Korean Gene Therapies On Horizon, But Slow Regulatory Changes A Drag
Executive Summary
While Korean companies are actively pursuing development of gene therapies, various regulatory restrictions at home are keeping them from speeding up development. But global development continues apace, with interim Phase III results for some expected later this year.
You may also be interested in...
Gene And Cell Therapies In Asia: New Korean Law To Change Landscape Of Cutting Edge Biologics
South Korea will undergo many changes as it gears up for a new law on cutting edge regenerative medicine and biologics, which will be implemented next year. Until then, further discussions will be needed to set details of the rules that can step up the industry’s competitiveness and bring the country more in line with global standards.
Gene And Cell Therapies In Asia: New Korean Law To Change Landscape Of Cutting Edge Biologics
South Korea will undergo many changes as it gears up for a new law on cutting edge regenerative medicine and biologics, which will be implemented next year. Until then, further discussions will be needed to set details of the rules that can step up the industry’s competitiveness and bring the country more in line with global standards.
Interview: ViroMed On Pricing, Manufacturing World’s First Broadly Used Gene Therapy
The head of global business strategy at ViroMed, one of the gene therapy companies nearing the commercial stage in the US, talks exclusively to Scrip about the South Korean biotech’s strategies, including for pricing and manufacturing, which are emerging as key considerations for developers.